ACADIA Pharmaceuticals (NASDAQ:ACAD) initiated with Market Perform rating and $44 (5% upside) price target at Oppenheimer.
Nektar Therapeutics (NASDAQ:NKTR) initiated with Market Perform rating and $18 (7% upside) price target at Oppenheimer.
Neovasc (NASDAQ:NVCN) initiated with Buy rating and $9 (151% upside) price target at H.C. Wainwright. Shares up 7% premarket.
Nephros (NASDAQ:NEPH) initiated with Speculative Buy rating and $16 (66% upside) price target at Benchmark.
PDS Biotechnology (NASDAQ:PDSB) initiated with Buy rating and $10 (212% upside) at Chardan Capital Markets. Shares up 17% premarket.
Acorda Therapeutics (NASDAQ:ACOR) downgraded to Underweight at JPMorgan. Shares down 13% premarket.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) downgraded to Neutral with a $39 (flat) price target at Baird. Shares down 2% premarket.
LaMaitre Vascular (NASDAQ:LMAT) downgraded to Outperform from Strong Buy at First Analysis. Shares down 2% premarket.
https://seekingalpha.com/news/3509090-chardan-likes-pds-bio-premarket-analyst-action
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.